Medpace Holdings Revises 2024 Revenue Forecast From $2.15B - $2.20B To $2.125B - $2.175B (Est $2.17B), EPS From $10.79 - $11.47 To $11.24 - $11.93 (Est $11.25)
Portfolio Pulse from Benzinga Newsdesk
Medpace Holdings has revised its 2024 revenue forecast from $2.15B - $2.20B to $2.125B - $2.175B, slightly below the estimated $2.17B. The EPS forecast has been adjusted from $10.79 - $11.47 to $11.24 - $11.93, above the estimated $11.25. GAAP net income for 2024 is expected to be between $361.0 million and $383.0 million, and EBITDA is forecasted to be in the range of $430.0 million to $460.0 million.
July 22, 2024 | 8:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Medpace Holdings has revised its 2024 revenue forecast slightly downward but has increased its EPS forecast, which is above estimates. GAAP net income and EBITDA forecasts are also provided.
The slight downward revision in revenue forecast may cause some concern, but the increase in EPS forecast, which is above estimates, is likely to have a positive impact on the stock price. The provided GAAP net income and EBITDA forecasts add further clarity and stability to the financial outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100